Form 4: OnKure Therapeutics Insider Option Grant

Dylan Hartley, Chief Scientific Officer at OnKure Therapeutics, Inc., was granted 110,000 employee stock options.

Summary

• Dylan Hartley, Chief Scientific Officer at OnKure Therapeutics, Inc., received an employee stock option grant.
• The option grant is for 110,000 shares of Class A Common Stock.
• The exercise price for these options is $4.07 per share.
• The options have an expiration date of March 31, 2036.
• Vesting begins on May 1, 2026, with 1/48th of the shares vesting monthly thereafter, contingent on continued service.
• The earliest transaction date reported is April 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive stock option grant without providing any operational or financial performance data.

Positives

• Grant of stock options to a key executive (Chief Scientific Officer) can align management incentives with shareholder value.
• The long expiration date (March 31, 2036) provides a significant long-term incentive.

Negatives

• The filing only details an option grant and does not provide financial performance or operational updates, making it difficult to assess overall company health from this document alone.

Risks

• Vesting is contingent on continued service, meaning the executive could forfeit unvested options if employment terminates.
• The value of the options is subject to the future stock price performance of OnKure Therapeutics, Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction. It solely reports on an insider stock option grant.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives is a common practice in the biotechnology and pharmaceutical sectors, aimed at retaining talent and aligning their interests with long-term company growth and value creation.

Stakeholder Impact

• Shareholders: The grant of options to a key executive can be seen as a positive incentive for long-term value creation, but the dilutive effect of future share issuance upon exercise should be considered.

Next Steps

• The options will vest monthly starting May 1, 2026, subject to continued employment.
• The options can be exercised until their expiration on March 31, 2036.

Key Dates

Keywords

stock options, insider trading, OnKure Therapeutics, Dylan Hartley, executive compensation, vesting schedule, SEC Form 4, OKUR